Platform of Polymeric Conjugates
for Selective Intracorporeal Removal
of Specific Harmful Antibodies

We are a multidisciplinary team with complementary profiles and proven experience in managing, developing, and commercializing R+D+i projects.

We truly believe that our strategy will greatly impact the patient’s health by changing the paradigm of treatment for antibody-mediated medical conditions.

Dr. Rafael Mañez
President & CMO

Dr. Daniel Bello
CSO

Montserrat Tarrés Ferrán
CCO

Pablo Madrazo
CEO

Dr. Sara Olivera Ardid
Clinical and R&D Operations Manager

Yara Ferrero Alves
Specialist Technician

Dr. Víctor Mejías Pérez
Scientific Project Manager

Scroll to Top